RT Journal Article
SR Electronic
T1 Corticospinal suppression underlying intact movement preparation fades in late Parkinson’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.03.22269055
DO 10.1101/2022.02.03.22269055
A1 Wilhelm, Emmanuelle
A1 Quoilin, Caroline
A1 Derosiere, Gerard
A1 Paço, Susana
A1 Jeanjean, Anne
A1 Duque, Julie
YR 2022
UL http://medrxiv.org/content/early/2022/02/04/2022.02.03.22269055.abstract
AB In Parkinson’s disease, neurophysiological abnormalities within the primary motor cortex have been shown to contribute to cardinal symptoms such as bradykinesia, but the exact modalities are still uncertain. Here, we propose that such impairment could involve alterations of mechanisms shaping motor activity specifically during voluntary movement preparation. Indeed, several past studies in healthy populations have suggested that a strong suppression of corticospinal excitability called “preparatory suppression” – propels movement execution by increasing motor neural gain. Thus, we hypothesized that a gradual alteration to this mechanism may contribute to progressive motor slowness in Parkinson’s disease. We also predicted a benefit of dopamine medication in restoring correct motor neural activity during action preparation.To test these hypotheses, we investigated preparatory suppression on two consecutive days in 29 Parkinson’s disease patients (ON and OFF medication) and 29 matched healthy controls. Single-pulse transcranial magnetic stimulation was applied over both primary motor cortices, eliciting concurrent motor-evoked potentials in the two hands, while subjects were either at rest or prepared a left- or right-hand response in an instructed-delay choice reaction time task. Preparatory suppression was assessed by expressing the amplitude of motor potentials evoked during movement preparation relative to those obtained at rest. These neurophysiological measures were cross-analysed with task behaviour and clinical data.Contrary to healthy controls, Parkinson’s disease patients showed a lack of preparatory suppression, which appeared to depend on disease progression, but not on dopamine medication. Indeed, in relatively early disease stages, patients still exhibited partial preparatory suppression, while in later stages, they lacked it completely and even exhibited a tendency for corticospinal facilitation in the hand selected for movement execution. As expected, patients also showed increasing motor handicap with disease progression as well as a decreased movement velocity during the task, but such findings did not directly correlate with levels of preparatory suppression in our cohort. While dopamine medication had no effect on the latter, it did however globally reduce raw corticospinal excitability in the dominant hand.Taken together, our results are in line with the idea that a lack of corticospinal suppression during movement preparation in Parkinson’s disease slows down response execution and illustrate the importance of considering disease stages in such investigations; they also suggest differential roles of dopamine in shaping corticospinal output in those patients. Our findings thus support the use of task-related functional markers such as preparatory suppression in future studies on motor impairment in Parkinson’s disease.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05209516Funding StatementThis work was supported by grants from the ''Fonds Speciaux de Recherche'' (FSR; IONS-FSR16 DUQUE) of the Universite catholique de Louvain, the Belgian National Funds for Scientific Research (FRS-FNRS; 1.A938.18) and the ''Fondation Medicale Reine Elisabeth'' (FMRE). At the time the research project was run, EW was a doctoral student supported by the L'Oreal-UNESCO ''For Women in Science'' program and the FRS-FNRS. CQ and GD were postdoctoral fellows supported by the FRS-FNRS.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participants were naive to the purpose of the study and gave written informed consent, following a protocol approved by the Biomedical Ethics Committee of the Saint-Luc University Hospital (UCLouvain, Brussels, Belgium; 2018/27AVR/194 - B403201836769), in accordance with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsDRTdopamine replacement therapyFDIfirst dorsal interosseousHChealthy controlM1primary motor cortexLOESSlocally estimated scatterplot smoothingMDS-UPDRSMovement Disorder Society Unified Parkinson’s Disease Rating ScaleMEP= motor evoked potentialMTmovement timeOLSordinary least squaresPCAprincipal component analysisRTreaction timeTMStranscranial magnetic stimulation